Your session is about to expire
← Back to Search
Radioactive Drug vs Everolimus for Neuroendocrine Cancer
Study Summary
This trial compares a radioactive drug linked to a peptide receptor with a drug that stops cancer cells from reproducing to treat neuroendocrine tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have used medication to manage carcinoid syndrome symptoms.My heart condition is not well-managed and is severe.I am 18 years old or older.I have a low-grade cancer originating from the midgut.I've had 3 or 4 rounds of PRRT therapy with a specific dose in the last year.I can attend all treatment, check-up, and follow-up appointments.I cannot swallow pills or have a gut condition affecting drug absorption.I have brain metastases that have not been treated.My cancer has grown after previous radiation therapy.I will take a pregnancy test if I can have children.I can get everolimus for my treatment.I am HIV positive, on treatment, and my viral load is undetectable.I have not had major surgery in the last 6 weeks.I have a serious health condition that isn't managed with treatment.I can take care of myself and am up and about more than 50% of my waking hours.I have another cancer that does not affect my current treatment's safety or effectiveness.
- Group 1: Arm I (177Lu-DOTATATE)
- Group 2: Arm II (everolimus)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participation in this research endeavor?
"Yes, according to the information on clinicaltrials.gov this is an ongoing medical trial which was first advertised on June 5th 2023 and last updated two weeks later. The research team seeks 100 participants at a single site."
Are there any detrimental effects to Arm I (177Lu-DOTATATE) for patients?
"With some available evidence of safety, our team at Power assigned Arm I (177Lu-DOTATATE) a rating of 2 on the 1 to 3 scale. The lack of efficacy data indicates that this is still in its Phase 2 trial phase."
Are there opportunities for enrolment in this research endeavor?
"Affirmative. According to the clinicaltrials.gov page, this research study is actively recruiting participants. It was first posted on June 5th 2023 and has been recently updated on June 23rd 2023; it seeks 100 volunteers from a single medical facility."
Share this study with friends
Copy Link
Messenger